Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DDRD2HRH1HTR2AHTR2CSLC6A2
The experimentally established mechanism targets of Trimipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.83 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.83 |
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.49 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.49 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.49 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.49 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.83 |
| ▸ | LMNA | P02545 | 6/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.83 |
| ▸ | DRD3 | P35462 | 6/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.83 |
| ▸ | HTR1A | P08908 | 5/20 | 0.83 |
| ▸ | DRD1 | P21728 | 5/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimipramine SCHEMBL35144 | 0.91 | SLC6A4 (1.00) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL29373768 | 0.91 | SLC6A4 (1.00) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL117756 | 0.91 | SLC6A4 (1.00) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL5494378 | 0.91 | SLC6A4 (1.00) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL4081184 | 0.90 | SLC6A4 (0.97) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL7597041 | 0.90 | SLC6A4 (0.97) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL30533075 | 0.90 | SLC6A4 (0.97) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL6511858 | 0.82 | CHRM1 (0.82) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| Trimipramine SCHEMBL6511859 | 0.82 | CHRM1 (0.82) | SLC6A4LMNACHRM1ADRA1ADRD3 | |
| SCHEMBL2615203 | 0.81 | LMNA (0.80) | SLC6A4LMNACHRM1ADRA1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3977138-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | Quest Diagnostics Investments LLC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114127554-A | Determination of antidepressants by mass spectrometry | 奎斯特诊断投资有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20250349528-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12394612-B2 | Determination of antidepressants by mass spectrometry | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-08-19 | — | — | US | disclosed |
| CN-114127554-B | Determination of antidepressants by mass spectrometry | 奎斯特诊断投资有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20240120188-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2024-04-11 | — | — | US | disclosed |
| US-11887828-B2 | Determination of antidepressants by mass spectrometry | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3977138-A1 | DETERMINATION OF ANTIDEPRESSANTS BY MASS SPECTROMETRY | Quest Diagnostics Investments LLC (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114127554-A | Determination of antidepressants by mass spectrometry | 奎斯特诊断投资有限公司 | 2022-03-01 | — | — | CN | disclosed |